Previous 10 | Next 10 |
home / stock / sls / sls articles
Shares of Ovid Therapeutics Inc (NASDAQ:OVID) dipped 65.7% to $1.1285 after Takeda’s Skyline study in Dravet syndrome missed its primary endp...
Investors might want to bet on Galena Biopharma, Inc. (NASDAQ: SLS), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in ...
– Based on the Efficacy and Safety Data Assessed, the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Tria...
NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage ...
- Update on the Phase 3 REGAL Clinical Trial of GPS in Acute Myeloid Leukemia (AML) - - Update on the Phase 2a Clinical Trial of SLS009 in rel...
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling over 200 points on Friday. The Dow traded down 0.55% to 38,692...
Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued...
U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 100 points on Friday. The Dow traded down 0.37% to 38,761.74...
U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 100 points on Friday. Following the market opening Friday, the D...
News, Short Squeeze, Breakout and More Instantly...
SELLAS Life Sciences Group Inc. Company Name:
SLS Stock Symbol:
NASDAQ Market:
SELLAS Life Sciences Group Inc. Website:
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
- Acute Myeloid Leukemia (AML) is the Second Most Common Hematological Malignancy in Children Often Associated with Poorer Prognosis Compared to Other Pediatric Cancers – - This Recognition Marks SELLAS’ Second RPDD Following the Designation for ALL Received Last Month - -...
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...